Hi Sheri,
You know I don't know much about CMML but I found this study about Vidaza (Azacitidine) in CMML patients:
https://ash.confex.com/ash/2011/webp...aper37800.html
"
Conclusion:
In this population of CMML patients with generally poor prognostic features, the overall response rates were 43% and overall survival 21 mo with Vidaza treatment and similar to that previously reported in higher risk MDS.
No significant predictive factors for response to Vidaza were identified, but marrow blast %, increased WBC count and spleen enlargement were adverse prognostic factors for survival.
Hope your mother will respond!
Kind regards
Birgitta-A